Global Harmonization Of Combination Product Regulation: EU vs US
This article was originally published in Clinica
Wherever you are in the world, the regulation of many different drug/device combination products is highly complex and costly. Yet the number of products being developed in combination is soaring. In this article, Neil O'Flaherty and Roberto Cursano, partners at law firm Baker & McKenzie, review the likelihood of global regulatory harmonization in this area, focusing on the differences between the EU and the US
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.